Zymeworks (NASDAQ:ZYME) to Buy Back $200 million in Outstanding Shares

Zymeworks (NASDAQ:ZYME – Get Free Report) announced that its Board of Directors has initiated a stock buyback plan on Monday, November 16th, RTT News reports. The company plans to repurchase $200 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 10.9% of its shares through open market purchases. Share repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

Several research analysts have recently weighed in on ZYME shares. Citigroup upped their target price on shares of Zymeworks from $39.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, November 11th. TD Cowen lifted their price target on shares of Zymeworks from $34.00 to $39.00 and gave the stock a “buy” rating in a research note on Tuesday, November 10th. Truist Financial boosted their price objective on shares of Zymeworks from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. B. Riley Financial reissued a “buy” rating and issued a $44.00 price objective (up from $40.00) on shares of Zymeworks in a research report on Monday, August 10th. Finally, Deutsche Bank set a $32.00 price objective on shares of Zymeworks in a research report on Wednesday, August 26th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

Read Our Latest Report on Zymeworks

Zymeworks Stock Up 0.8%

Shares of NASDAQ ZYME opened at $26.04 on Thursday. The stock’s 50 day moving average price is $27.20 and its two-hundred day moving average price is $25.53. Zymeworks has a 52-week low of $21.52 and a 52-week high of $31.97. The stock has a market capitalization of $1.80 billion, a P/E ratio of 50.08 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported $2.28 EPS for the quarter, topping the consensus estimate of $2.27 by $0.01. Zymeworks had a return on equity of 22.23% and a net margin of 16.10%. The company had revenue of $512.92 million during the quarter, compared to analyst estimates of $227.40 million. During the same quarter last year, the firm earned ($0.26) EPS. The business’s revenue was up 828.7% on a year-over-year basis. On average, analysts anticipate that Zymeworks will post 1.31 EPS for the current year.

Insider Activity at Zymeworks

In other Zymeworks news, insider Paul Moore sold 39,741 shares of Zymeworks stock in a transaction on Friday, November 13th. The shares were sold at an average price of $26.07, for a total value of $1,036,047.87. Following the completion of the transaction, the insider owned 33,756 shares of the company’s stock, valued at $880,018.92. The trade was a 54.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Adam Schayowitz sold 13,832 shares of the business’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $25.85, for a total transaction of $357,557.20. Following the sale, the executive vice president owned 23,205 shares of the company’s stock, valued at approximately $599,849.25. The trade was a 37.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 37.73% of the company’s stock.

Zymeworks Company Profile

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Featured Stories

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.